The five-year survival rate for women with ovarian cancer has only improved incrementally over the last decade. Widespread metastasis still remains a major challenge.
Anil Sood, M.D., and his colleagues have learned that a gene-silencing therapy can effectively shut off cancer-catalyzing genes without damaging healthy cells. A drug called EpharnaTM allows for the silencing of EphA2, an ovarian cancer oncogene, resulting in the shrinking of tumors.
With support from the Bettyann Asche Murray Distinguished Professorship in Ovarian Cancer Research, Dr. Sood and colleagues have focused on bringing this therapy into the clinic. They are also developing additional methods for more effectively targeting the drug directly to cancer cells while sparing healthy ones.
You can further the pursuits of established oncology leaders.
Fund a professorship for a minimum of $400,000.
Call 713-563-4084 for more information.
These findings can make chemotherapy more effective and apply across numerous types of cancer.”
Anil Sood, M.D.
Professor, Gynecologic Oncology and Reproductive Medicine